Pandion Therapeutics Inc. Common Stock
PAND
PAND was delisted on the 31st of March, 2021.
52 hedge funds and large institutions have $121M invested in Pandion Therapeutics Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 52 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$36M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$30.3M |
| 3 |
O
OrbiMed
New York
|
+$25.3M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$19.1M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$10.3M |
Top Sellers
PAND Hedge Fund Activity: Q3 2020 in Review
52 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Pandion Therapeutics Inc. Common Stock (PAND) for Q3 2020, worth a combined $121M.
Buyers outnumbered sellers: 52 funds opened new PAND positions and 0 closed out — a net gain of 52 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Boxer Capital, opening a new position worth an estimated $36M.
- 52 institutional investors held Pandion Therapeutics Inc. Common Stock (PAND) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $121M of Pandion Therapeutics Inc. Common Stock stock for Q3 2020.
- 52 funds opened new Pandion Therapeutics Inc. Common Stock positions in Q3 2020 and 0 closed out, a net change of +52 holders.
- The largest Pandion Therapeutics Inc. Common Stock buyer in Q3 2020 was Boxer Capital, an estimated $36M added.
Based on aggregated 13F filings for Q3 2020.